12 completed, 3 unknown, 1 terminated, 1 withdrawn. 17 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 12, Unknown 3, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Ipratropium: new trials by email Literature Review of Ipratropium trials Research Report on Ipratropium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible Bronchoscopy Glycopyrronium, Ipratropium, Saline - Subjects Undergoing Flexible Bronchoscopy | Phase 2 / Phase 3 | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 1050 | 2024-04-24 | 2024-04-22 |
| Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Ipratropium / Levosalbutamol Fixed Dose Combination, Ipratropium + Levosalbutamol Free Dose Combination - COPD | Phase 3 | Unknown | Neutec Ar-Ge San ve Tic A.Ş | 74 | 2023-09-28 | 2023-10-03 |
| Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Ipratropium / Levosalbutamol Fixed Dose Combination, Ipratropium + Levosalbutamol Free Dose Combination - COPD | Phase 3 | Unknown | Neutec Ar-Ge San ve Tic A.Ş | 74 | 2023-08-25 | 2023-09-05 |
| Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI, Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI - Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Neutec Ar-Ge San ve Tic A.Ş | 2021-09-03 | 2021-09-13 | |
| The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia Albuterol-sulphate, Ipratropium-bromide, placebo - Familial Dysautonomia | Phase 3 | Completed | NYU Langone Health | 15 | 2013-03-01 | 2016-06-02 |
| Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease Combivent CFC-MDI, Combivent Respimat 20/100 mcg, Atrovent HFA 42 mcg + Albuterol HFA 200 mcg - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 470 | 2009-11-01 | 2014-10-23 |
| Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room. Budesonide, albuterol, Ipratropium bromide - Asthma | Phase 3 | Completed | Northwell Health | 95 | 2007-09-01 | 2016-01-21 |
| A Crossover Study in the Treatment of Patients With COPD Formoterol Fumurate inhalation solution 20 mcg, Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Dey | 100 | 2007-05-01 | 2009-03-04 |
| Magnesium Sulfate Versus Ipratropuim Bromide in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Ipratropium bromide, Magnesium Sulfate - COPD Exacerbation | Phase 3 | Completed | University of Monastir | 124 | 2005-01-01 | 2010-06-03 |
| Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva Tiotropium + placebo, Tiotropium + ipratropium, Tiotropium + fenoterol - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 65 | 2002-10-01 | 2013-11-01 |
| Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease Ipratropium bromide / Salbutamol, Placebo Inhalation solution, Ipratropium bromide - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 1118 | 2002-10-01 | 2014-06-27 |
| Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPD Tiotropium, Ipratropium - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 141 | 2002-07-01 | 2013-11-01 |
| Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease tiotropium inhalation powder capsules, Atrovent, placebo to Atrovent - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 50 | 2001-06-01 | 2018-08-31 |
| Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Tiotropium inhalation powder capsule, Placebo Metered Dose Inhaler, Ipratropium Bromide Metered Dose Inhaler - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 215 | 2001-05-01 | 2014-06-24 |
| Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease Low dose of Ipratropium bromide, High dose of Ipratropium bromide, Atrovent - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 646 | 1998-08-01 | 2014-07-17 |
| Efficacy and Safety of Combivent® Aerosol and Spacer, in Adult Patients With Moderate to Severe Asthma Crisis salbutamol sulfate + ipratropium bromide - Asthma | Phase 3 | Terminated | Boehringer Ingelheim | 47 | 1998-07-01 | 2014-07-08 |
| Lung Health Study (LHS) I and III smoking cessation, ipratropium - Lung Diseases, Lung Diseases, Obstructive | Phase 3 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 1984-09-01 | 2016-04-14 |
Pulmonary Disease, Chronic Obstructive (12) · Asthma (2) · Dysautonomia, Familial (1) · Emergencies (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1)
Boehringer Ingelheim (8) · Neutec Ar-Ge San ve Tic A.Ş (3) · Dey (1) · NYU Langone Health (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Northwell Health (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · University of Monastir (1)
United States (4) · Turkey (Türkiye) (2) · India (1) · Netherlands (1) · South Korea (1) · Tunisia (1)
Hakan Gunen, Professor Doctor (1) · Ismail Hanta, Professor Doctor (1) · John Connett (1) · Robert Silverman, MD (1)
PMID 17890476, PMID 19232039, PMID 23658479, PMID 26024688, PMID 27486205, PMID 29631575